NeuroMetrix, Inc. Announces Date for 2011 Third Quarter Financial Results Conference Call WALTHAM, Mass., Oct 20, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2011 third quarter financial results before the opening of the market on October 27, 2011.

Updates on NC-stat DPNCheck Commercial Launch

NeuroMetrix to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 29, 2011-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of

NeuroMetrix Reports Commercial Milestone 100th NC-stat® DPNCheck™ Order WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 28, 2011-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced the achievement

NeuroMetrix to Present at 5th Annual OneMedForum San Francisco 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 3, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Shai N.

NeuroMetrix Announces Pricing of Securities Offering WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 8, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has priced a public offering of up to 10,500,000 Units at a price per Unit of $1.00 , for aggregate gross proceeds of up to $10,500,000 ,

NeuroMetrix, Inc. Announces Date for 2011 Fourth Quarter Financial Results Conference Call WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 10, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2011 fourth quarter financial results before the opening of the market on February 15, 2012

Closes $8.5 Million Public Offering of Common Stock and Warrants

Will Support a Hands-On Workshop on Evaluation of Diabetic Peripheral Neuropathy

NeuroMetrix Announces Warrant Redemption WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 13, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes, today announced plans to redeem warrants to purchase an aggregate